Assembly Bioscie Financials
Assembly Bioscie (ASMB) reported $72.3M in revenue for fiscal year 2025, up 153.5% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Accounting losses narrowed fast in FY2025, but cash consumption still reflects a research-driven business funded externally.
In FY2025, net loss was only$6.1M while operating cash flow was-$41.1M , so the better earnings picture did not translate into cash. With R&D still at$64.8M and capex just$66K , the burn is coming from ongoing research activity rather than from maintaining a capital-heavy operating base.
FY2025's liquidity improvement came from financing, not from self-funding: a
The income statement shows clear operating leverage: operating margin improved from
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Assembly Bioscie's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Not available for Assembly Bioscie, and counted as zero in the overall score.
Assembly Bioscie scores 4.69, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($689.0M) relative to total liabilities ($50.8M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Assembly Bioscie passes 3 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.
Assembly Bioscie reported a net loss of $6.1M while operations used $41.1M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Assembly Bioscie generated $72.3M in revenue in fiscal year 2025. This represents an increase of 153.5% from the prior year.
Assembly Bioscie's EBITDA was -$12.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 73.5% from the prior year.
Assembly Bioscie reported -$6.1M in net income in fiscal year 2025. This represents an increase of 84.8% from the prior year.
Cash & Balance Sheet
Assembly Bioscie recorded an outflow of $41.2M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents an increase of 19.5% from the prior year.
Assembly Bioscie held $58.5M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Assembly Bioscie's operating margin was -16.8% in fiscal year 2025, reflecting core business profitability. No change is given against fiscal year 2024: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Assembly Bioscie's net profit margin was -8.5% in fiscal year 2025, showing the share of revenue converted to profit. No change is given against fiscal year 2024: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Assembly Bioscie's ROE was -3.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 117.5 percentage points from the prior year.
Not reported for fiscal year 2025.
Capital Allocation
Assembly Bioscie invested $64.8M in research and development in fiscal year 2025. This represents an increase of 15.9% from the prior year.
Assembly Bioscie invested $66K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 135.7% from the prior year.
Not reported for fiscal year 2025.
ASMB Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $74.8M | $72.3M+153.5% | $28.5M+298.2% | $7.2M | $0-100.0% | $6.3M-92.1% | $79.1M+395.6% | $16.0M+7.8% | $14.8M+64.1% | $9.0M | $0 | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $63.7M | $64.8M+15.9% | $55.9M+14.4% | $48.9M-30.1% | $70.0M+2.1% | $68.5M-35.9% | $106.8M+24.6% | $85.8M+17.9% | $72.7M+64.5% | $44.2M+33.6% | $33.1M+80.3% | $18.4M+71.3% | $10.7M-28.7% | $15.0M-23.0% | $19.5M-22.8% | $25.3M |
| SG&A Expenses | $20.0M | $19.6M+8.9% | $18.0M-21.4% | $22.9M-5.1% | $24.1M-16.1% | $28.8M-22.3% | $37.1M+12.6% | $32.9M-5.4% | $34.8M+104.4% | $17.0M+39.7% | $12.2M+7.9% | $11.3M-14.7% | $13.2M+189.3% | $4.6M-14.3% | $5.3M-38.8% | $8.7M |
| Operating Income | -$8.8M | -$12.1M+73.3% | -$45.4M+29.7% | -$64.6M+31.3% | -$94.1M+29.1% | -$132.7M-104.8% | -$64.8M+36.9% | -$102.7M-10.8% | -$92.7M-77.6% | -$52.2M-15.3% | -$45.3M-52.7% | -$29.7M-23.8% | -$24.0M-22.2% | -$19.6M+21.1% | -$24.9M+26.9% | -$34.0M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $117K |
| Income Tax | N/A | $0-100.0% | $330K+900.0% | $33K | $0+100.0% | -$2.5M | $0+100.0% | -$774K-170.4% | $1.1M+112.1% | -$9.1M-1364.4% | -$618K | $0 | $0 | N/A | N/A | N/A |
| Net Income | -$42K | -$6.1M+84.8% | -$40.2M+34.4% | -$61.2M+34.2% | -$93.1M+28.3% | -$129.9M-108.9% | -$62.2M+36.3% | -$97.6M-7.6% | -$90.8M-112.0% | -$42.8M+3.3% | -$44.3M-55.6% | -$28.5M-19.6% | -$23.8M-22.6% | -$19.4M+21.7% | -$24.8M+27.8% | -$34.3M |
| EPS (Diluted) | — | -$0.55 | -$6.69+50.0% | -$13.38+42.0% | -$23.08 | -$3.00 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
ASMB Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $257.6M+116.2% | $119.2M-12.9% | $136.8M+34.4% | $101.8M-46.7% | $191.1M-32.5% | $283.3M-16.7% | $339.9M+26.8% | $268.0M+58.3% | $169.3M+72.6% | $98.1M-26.6% | $133.7M+87.8% | $71.2M+162.5% | $27.1M+32.0% | $20.6M-44.5% | $37.0M |
| Current Assets | $254.5M+120.4% | $115.5M-13.7% | $133.8M+38.0% | $97.0M-37.1% | $154.2M-31.3% | $224.5M-20.6% | $282.8M+27.1% | $222.5M+80.7% | $123.1M+129.8% | $53.6M-21.6% | $68.4M+134.0% | $29.2M+7.7% | $27.1M+32.0% | $20.5M-44.5% | $37.0M |
| Cash & Equivalents | $58.5M+52.4% | $38.3M+93.3% | $19.8M-62.1% | $52.4M+14.9% | $45.6M-23.2% | $59.4M+27.2% | $46.7M+12.7% | $41.5M-49.4% | $82.0M+187.1% | $28.6M+5.4% | $27.1M-6.8% | $29.1M+7.5% | $27.1M+32.1% | $20.5M-44.6% | $37.0M |
| Accounts Receivable | $974K | $0-100.0% | $43K-95.4% | $944K+181.0% | $336K-72.7% | $1.2M-63.5% | $3.4M+38.8% | $2.4M+6.9% | $2.3M | $0 | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | $12.6M0.0% | $12.6M0.0% | $12.6M0.0% | $12.6M0.0% | $12.6M0.0% | $12.6M-0.8% | $12.7M | $0 | N/A | N/A |
| Total Liabilities | $50.8M-40.8% | $85.8M-10.4% | $95.7M+400.4% | $19.1M-13.6% | $22.1M-48.1% | $42.7M-36.0% | $66.7M+16.2% | $57.4M+2.2% | $56.2M+208.0% | $18.2M+21.6% | $15.0M+18.6% | $12.7M+379.7% | $2.6M-3.9% | $2.7M+9.2% | $2.5M |
| Current Liabilities | $48.8M+2.0% | $47.8M+21.9% | $39.2M+140.7% | $16.3M+1.4% | $16.1M-34.2% | $24.4M0.0% | $24.4M+32.3% | $18.5M+36.9% | $13.5M+89.5% | $7.1M+109.3% | $3.4M+222.8% | $1.1M-60.0% | $2.6M | N/A | $2.5M |
| Total Equity | $206.8M+519.8% | $33.4M-18.8% | $41.1M-50.3% | $82.7M-51.1% | $168.9M-29.8% | $240.6M-11.9% | $273.2M+29.7% | $210.7M+86.2% | $113.1M+41.6% | $79.9M-32.7% | $118.7M+102.7% | $58.6M+139.1% | $24.5M+37.5% | $17.8M-48.4% | $34.5M |
| Retained Earnings | -$832.0M-0.7% | -$825.9M-5.1% | -$785.7M-8.5% | -$724.5M-14.7% | -$631.4M-25.9% | -$501.6M-14.1% | -$439.4M-28.6% | -$341.8M-36.2% | -$251.0M-20.6% | -$208.2M-27.0% | -$164.0M-21.0% | -$135.5M-21.3% | -$111.7M | N/A | N/A |
Not reported in any period shown, so not listed: Inventory, Long-Term Debt.
ASMB Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$38.5M | -$41.1M+19.6% | -$51.1M-324.8% | $22.7M+126.9% | -$84.5M+9.6% | -$93.4M-48.3% | -$63.0M+25.1% | -$84.1M-29.4% | -$65.0M-3592.4% | $1.9M+105.3% | -$34.9M-86.6% | -$18.7M-24.9% | -$15.0M+15.9% | -$17.8M+16.8% | -$21.4M+14.7% | -$25.1M |
| Capital Expenditures | $85K | $66K+135.7% | $28K-89.0% | $255K+150.0% | $102K-96.7% | $3.1M+558.7% | $470K-69.8% | $1.6M+357.1% | $340K-60.7% | $865K+488.4% | $147K+152.3% | $58K-61.1% | $150K+2215.3% | $6K+99.8% | $3K-72.9% | $12K |
| Free Cash Flow | -$38.6M | -$41.2M+19.5% | -$51.1M-327.4% | $22.5M+126.6% | -$84.6M+12.4% | -$96.5M-52.1% | -$63.4M+25.9% | -$85.6M-31.1% | -$65.3M-6662.6% | $995K+102.8% | -$35.0M-86.8% | -$18.8M-24.0% | -$15.1M+15.0% | -$17.8M+16.7% | -$21.4M+14.7% | -$25.1M |
| Investing Cash Flow | -$234.5M | -$113.5M-382.5% | $40.2M+158.1% | -$69.1M-176.3% | $90.6M+241.8% | $26.5M-61.0% | $68.1M+235.3% | -$50.3M+62.8% | -$135.4M-765.6% | -$15.6M-143.2% | $36.2M+155.8% | -$64.9M-23479.7% | $277K+4382.9% | -$6K-99.8% | -$3K+72.9% | -$12K |
| Financing Cash Flow | $281.3M | $174.7M+493.1% | $29.4M+113.1% | $13.8M+2150.5% | $614K-98.8% | $53.1M+598.3% | $7.6M-94.6% | $139.6M-12.6% | $159.8M+137.6% | $67.2M+43847.7% | $153K-99.8% | $81.6M+387.7% | $16.7M-31.4% | $24.4M+397.8% | $4.9M-89.7% | $47.5M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
ASMB Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -16.8% | -159.3% | -902.5% | N/A | -2121.7% | -81.9% | -643.4% | -626.4% | -579.1% | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | -8.5% | -140.9% | -854.8% | N/A | -2076.3% | -78.6% | -611.6% | -613.0% | -474.7% | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | -3.0%+117.5pp | -120.4%+28.5pp | -149.0%-36.4pp | -112.6%-35.7pp | -76.9%-51.0pp | -25.8%+9.9pp | -35.7%+7.4pp | -43.1%-5.2pp | -37.8%+17.6pp | -55.4%-31.4pp | -24.0%+16.7pp | -40.6%+38.6pp | -79.2%+60.0pp | -139.2%-39.7pp | -99.5% |
| Return on Assets | -2.4%+31.3pp | -33.7%+11.0pp | -44.8%+46.7pp | -91.5%-23.5pp | -68.0%-46.0pp | -21.9%+6.8pp | -28.7%+5.1pp | -33.9%-8.6pp | -25.3%+19.8pp | -45.1%-23.8pp | -21.3%+12.1pp | -33.4%+38.1pp | -71.5%+49.1pp | -120.6%-27.9pp | -92.7% |
| Current Ratio | 5.22+2.8x | 2.42-1.0x | 3.41-2.5x | 5.95-3.6x | 9.59+0.4x | 9.19-2.4x | 11.57-0.5x | 12.05+2.9x | 9.13+1.6x | 7.52-12.6x | 20.09-7.6x | 27.72+17.4x | 10.28 | N/A | 14.74 |
| Debt-to-Equity | 0.25-2.3x | 2.57+0.2x | 2.33+2.1x | 0.23+0.1x | 0.130.0x | 0.18-0.1x | 0.240.0x | 0.27-0.2x | 0.50+0.3x | 0.23+0.1x | 0.13-0.1x | 0.22+0.1x | 0.110.0x | 0.15+0.1x | 0.07 |
| FCF Margin | -56.9% | -179.3% | 313.9% | N/A | -1542.9% | -80.2% | -536.4% | -441.1% | 11.0% | N/A | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Assembly Bioscie Ranks
Frequently Asked Questions
What is Assembly Bioscie's annual revenue?
Assembly Bioscie (ASMB) reported $72.3M in total revenue for fiscal year 2025. This represents a 153.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Assembly Bioscie's revenue growing?
Assembly Bioscie (ASMB) revenue grew by 153.5% year-over-year, from $28.5M to $72.3M in fiscal year 2025.
Is Assembly Bioscie profitable?
No, Assembly Bioscie (ASMB) reported a net income of -$6.1M in fiscal year 2025, with a net profit margin of -8.5%.
What is Assembly Bioscie's EBITDA?
Assembly Bioscie (ASMB) had EBITDA of -$12.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Assembly Bioscie's operating margin?
Assembly Bioscie (ASMB) had an operating margin of -16.8% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Assembly Bioscie's net profit margin?
Assembly Bioscie (ASMB) had a net profit margin of -8.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Assembly Bioscie's return on equity (ROE)?
Assembly Bioscie (ASMB) has a return on equity of -3.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Assembly Bioscie's free cash flow?
Assembly Bioscie (ASMB) recorded an outflow of $41.2M in free cash flow during fiscal year 2025. This represents a 19.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Assembly Bioscie's operating cash flow?
Assembly Bioscie (ASMB) recorded an outflow of $41.1M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Assembly Bioscie's total assets?
Assembly Bioscie (ASMB) had $257.6M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Assembly Bioscie's capital expenditures?
Assembly Bioscie (ASMB) invested $66K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Assembly Bioscie spend on research and development?
Assembly Bioscie (ASMB) invested $64.8M in research and development during fiscal year 2025.
What is Assembly Bioscie's current ratio?
Assembly Bioscie (ASMB) had a current ratio of 5.22 as of fiscal year 2025, which is generally considered healthy.
What is Assembly Bioscie's debt-to-equity ratio?
Assembly Bioscie (ASMB) had a debt-to-equity ratio of 0.25 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Assembly Bioscie's return on assets (ROA)?
Assembly Bioscie (ASMB) had a return on assets of -2.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Assembly Bioscie's cash runway?
Based on fiscal year 2025 data, Assembly Bioscie (ASMB) had $58.5M in cash against an annual operating cash burn of $41.1M. This gives an estimated cash runway of approximately 17 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Assembly Bioscie's Altman Z-Score?
Assembly Bioscie (ASMB) has an Altman Z-Score of 4.69, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Assembly Bioscie's Piotroski F-Score?
Assembly Bioscie (ASMB) has a Piotroski F-Score of 3 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Assembly Bioscie's earnings high quality?
Assembly Bioscie (ASMB) reported a net loss of $6.1M while operations used $41.1M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Assembly Bioscie?
Assembly Bioscie (ASMB) scores 57 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.